DK313989D0 - Farmaceutisk praeparat mod atherosclerose - Google Patents

Farmaceutisk praeparat mod atherosclerose

Info

Publication number
DK313989D0
DK313989D0 DK313989A DK313989A DK313989D0 DK 313989 D0 DK313989 D0 DK 313989D0 DK 313989 A DK313989 A DK 313989A DK 313989 A DK313989 A DK 313989A DK 313989 D0 DK313989 D0 DK 313989D0
Authority
DK
Denmark
Prior art keywords
atherosclerose
pharmaceutical preparation
preparation against
pharmaceutical
preparation
Prior art date
Application number
DK313989A
Other languages
English (en)
Other versions
DK313989A (da
Inventor
Andries Johannes Corne Strydom
Original Assignee
Andries Johannes Corne Strydom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andries Johannes Corne Strydom filed Critical Andries Johannes Corne Strydom
Publication of DK313989D0 publication Critical patent/DK313989D0/da
Publication of DK313989A publication Critical patent/DK313989A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK313989A 1988-06-24 1989-06-23 Farmaceutisk praeparat mod atherosclerose DK313989A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA884556 1988-06-24

Publications (2)

Publication Number Publication Date
DK313989D0 true DK313989D0 (da) 1989-06-23
DK313989A DK313989A (da) 1989-12-25

Family

ID=25579302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK313989A DK313989A (da) 1988-06-24 1989-06-23 Farmaceutisk praeparat mod atherosclerose

Country Status (8)

Country Link
EP (1) EP0347864A3 (da)
JP (1) JPH0267216A (da)
AU (2) AU3673789A (da)
DK (1) DK313989A (da)
IL (1) IL90732A0 (da)
MC (1) MC2041A1 (da)
NO (1) NO892617L (da)
NZ (1) NZ229670A (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1265295A (en) * 1993-12-10 1995-06-27 Sami A. Hashim Reducing likelihood of vascular disorders in susceptible patients
DE69501421T2 (de) * 1994-04-28 1998-04-23 Eisai Co Ltd Hematetrenome Derivat als antiarteriosklerotisches Mittel
AU5259296A (en) * 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
DE19538666A1 (de) * 1995-10-17 1997-04-24 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von arteriellen Verschlußkrankheiten, Mikroangiopathien und Mikrozirkulationsstörungen
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
KR100213895B1 (ko) * 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
CA2290381A1 (en) 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
EP1063988A1 (en) * 1997-10-28 2001-01-03 Korea Institute Of Science And Technology Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
BR9914815A (pt) * 1998-10-30 2001-07-03 Merck Patent Gmbh Composições para tratamento e prevenção de doenças cardiovasculares
ATE235244T1 (de) * 1998-10-30 2003-04-15 Merck Patent Gmbh Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
CN1159984C (zh) * 1999-06-29 2004-08-04 新西兰奶制品研究所有限公司 基于奶的预防性饮食添加剂
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
JP5080011B2 (ja) * 2005-02-28 2012-11-21 第一三共ヘルスケア株式会社 グルタチオンペルオキシダーゼ活性を増加させるための組成物
BRPI0610249A2 (pt) 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57197284A (en) * 1981-05-29 1982-12-03 Eiichi Suenaga Alpha-tocopheryl nicotinate metal complex, its preparation, and remedy for arteriosclerosis comprising it as active ingredient

Also Published As

Publication number Publication date
NO892617D0 (no) 1989-06-23
JPH0267216A (ja) 1990-03-07
NZ229670A (en) 1992-07-28
EP0347864A2 (en) 1989-12-27
MC2041A1 (fr) 1990-05-30
AU2999192A (en) 1993-02-04
IL90732A0 (en) 1990-01-18
EP0347864A3 (en) 1992-04-01
NO892617L (no) 1989-12-27
DK313989A (da) 1989-12-25
AU3673789A (en) 1990-01-04

Similar Documents

Publication Publication Date Title
DK229489D0 (da) Laegemiddeladsorbater
DK489189A (da) Farmaceutisk praeparat
DK481989A (da) Farmaceutiske formuleringer
DK89090D0 (da) Farmaceutisk praeparat
DK9089D0 (da) Praeparat til vaccine mod kokcidiose
DE10199066I1 (de) Pharmazeutische Zusammensetzung
DK540389D0 (da) Immunstimulerende praeparat
DK705488D0 (da) Farmaceutisk praeparat
DK313989D0 (da) Farmaceutisk praeparat mod atherosclerose
DK548689D0 (da) Farmaceutisk oploesning
DK603988D0 (da) Farmaceutisk praeparat
DK496889D0 (da) Peptidholdigt farmaceutisk praeparat
DK290989A (da) Farmaceutisk praeparat mod nephritis
DK336489D0 (da) Farmaceutisk praeparat
DK139388D0 (da) Farmaceutisk praeparat
DK276288D0 (da) Farmaceutisk praeparat
ATA321188A (de) Pharmazeutische zubereitung
DK606288D0 (da) Praeparat
DK37589A (da) Farmaceutisk praeparat for 4-aroylimidazol-2-oner
DK429589A (da) Transdermalt laegemiddelpraeparat
DK638889A (da) Farmaceutisk kombinationspraeparat
DK343689A (da) Herbicidt praeparat
IT1224244B (it) Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano
DK138888D0 (da) Farmaceutisk praeparat
DK650888D0 (da) Farmaceutisk praeparat med virkning mod cancer

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment